Liraglutide in Children and Adolescents with Type 2 Diabetes | Zendy

William V. Tamborlane | Zendy; Margarita BarrientosPérez | Zendy; Udi Fainberg | Zendy; Helle FrimerLarsen | Zendy; Mona Hafez | Zendy; Paula M. Hale | Zendy; Muhammad Yazid Jalaludin | Zendy; М. А. Коваренко | Zendy; Ingrid Libman | Zendy; Jane Lynch | Zendy; Paturi Rao | Zendy; Naim Shehadeh | Zendy; Serap Turan | Zendy; Daniel Weghuber | Zendy; Timothy Barrett | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Liraglutide in Children and Adolescents with Type 2 Diabetes

Author(s) -

William V. Tamborlane,

Margarita BarrientosPérez,

Udi Fainberg,

Helle FrimerLarsen,

Mona Hafez,

Paula M. Hale,

Muhammad Yazid Jalaludin,

М. А. Коваренко,

Ingrid Libman,

Jane Lynch,

Paturi Rao,

Naim Shehadeh,

Serap Turan,

Daniel Weghuber,

Timothy Barrett

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1903822

Subject(s) - liraglutide , type 2 diabetes , medicine , pediatrics , diabetes mellitus , endocrinology

Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research